Inquis Medical, a medical technology company specializing in advanced thrombectomy systems, announced the closing of its $40 million Series B funding round. This funding round was led by Marshall Wace (a globally recognized investment firm), with strong participation from existing investors, including ShangBay Capital, Yu Star, EnPointe Ventures, and Pierre Lamond. This funding positions Inquis Medical for significant growth and development as it advances its cutting-edge technologies and prepares for commercialization.
Inquis Medical is a clinical-stage medical device company that is dedicated to bringing next-generation thrombectomy systems to market. And its flagship product, the Aventus Precision Thrombectomy System, features proprietary tissue-sensing technology that provides operators with real-time information on the tissue composition in contact with the device. This system offers enhanced precision and control during procedures, pushing the boundaries of what current thrombectomy systems can achieve.
Earlier this year, Inquis had received FDA 510(k) clearance for its Aventus Thrombectomy System, and its blood return system for peripheral indications, and is nearing completion of enrollment in an FDA Investigational Device Exemption (IDE) pivotal clinical study targeting pulmonary embolism (PE) patients.
In connection with the Series B funding round, Andrew D. Goldberg, MD, a portfolio manager at Marshall Wace, has joined Inquis Medical’s Board of Directors.
This funding represents a significant milestone in Inquis Medical’s rapid development and will enable the company to complete its pivotal IDE trial, prepare for the commercial launch of the Aventus Thrombectomy System in 2025, and continue to advance its proprietary tissue-sensing platform.
In the U.S., there are about 1 million individuals are affected by venous thromboembolism (VTE) each year, with over 50% of deep vein thrombosis cases leading to pulmonary embolism (PE), which is the third leading cause of cardiovascular death. And current lytic-free aspiration thrombectomy procedures are often limited by significant blood loss and procedural inefficiencies, making Inquis Medical’s innovations a promising advancement in the field.
KEY QUOTES:
“We are thrilled to have successfully secured our Series B funding. This is a strong validation of the confidence investors have in our mission and the potential impact of our innovations.”
– Vahid Saadat, Co-CEO and Co-Founder of Inquis Medical
“This substantial investment from Marshall Wace, along with our existing investors, underscores a strong belief in both our technology and our team. We are excited for the next phase of the company and look forward to enhancing patient care by empowering physicians with our unique technology.”
– Mojgan Saadat, Co-CEO and Co-Founder
